Market Mover | Ainos Shares Soar 30% After the Company Reports Progress in Clinical Trials of Ainos Flora Testing Device
Market Mover | Ainos Shares Soar 30% After the Company Reports Progress in Clinical Trials of Ainos Flora Testing Device
June 14, 2024 - $Ainos (AIMD.US)$shares soared 30.46% to $1.07 in intraday trading on Friday. The company announced progress in the clinical trials of its Ainos Flora volatile organic compound point-of-care testing device.
2024年6月14日 - $Ainos (AIMD.US)$周五盘中股价飙升30.46％，达到1.07美元。该公司宣布其Ainos Flora挥发性有机化合物门诊测试设备的临床试验取得了进展。
The device is designed to provide rapid, non-invasive detection of bacterial, fungal, and sexually transmitted infections in women. The clinical trials have been conducted at four major medical centers in Taiwan, testing 75 clinical cases and demonstrating the effectiveness of the AI algorithm model with improved recognition accuracy.
该设备旨在为女性提供快速、非侵入性的细菌、真菌和性传播疾病检测服务。临床试验在台湾的四个主要医疗中心进行，测试了75个临床病例，并证明了AI算法模型具有更高的识别准确性。
Ainos is now developing the next generation of the Ainos Flora device, expanding the test portfolio to include viral infection and allowing users to obtain accurate results quickly and easily without professional medical training, further optimized for at-home testing. Clinical trials are planned to commence in the fourth quarter of this year.
Ainos现在正在开发Ainos Flora下一代设备，将测试组合扩大到病毒感染，并允许用户快速获得准确结果，而无需专业医学培训，进一步放宽家庭测试门槛。计划在今年第四季度开始开展临床试验。
Related Reading: Press Release
相关阅读：新闻发布